Moore, TH, Zammit, S, Lingford-Hughes, A, Barnes, TR, Jones, PB, Burke, M, Lewis, G.
Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review. Lancet
2007; 370: 319–32.
D'Souza, DC, Perry, E, MacDougall, L, Ammerman, Y, Cooper, T, Wu, YT, Braley, G, Gueorguieva, R, Krystal, JH.
The psychotomimetic effects of intravenous delta-9-tetrahydrocannabinol in healthy individuals: implications for psychosis. Neuropsychopharmacology
2004; 29: 1558–72.
Zuardi, AW, Crippa, JA, Hallak, JE, Moreira, FA, Guimaraes, FS.
Cannabidiol, a Cannabis sativa constituent, as an antipsychotic drug. Braz J Med Biol Res
2006; 39: 421–9.
Leweke, FM, Schneider, U, Radwan, M, Schmidt, E, Enrich, HM.
Different effects of nabilone and cannabidiol on binocular depth inversion in man. Pharmacol Biochem Behav
2000; 66: 175–81.
Hermann, D, Sartorius, A, Welzel, H, Walter, S, Skopp, G, Ende, G.
Dorsolateral prefrontal cortex N-acetylaspartate/total creatine (NAA/tCr) loss in male recreational cannabis users. Biol Psychiatry
2007; 61: 1281–9.
Ross, SA, Mehmedic, Z, Murphy, TP, Elsohly, MA.
GC-MS analysis of the total delta9-THC content of both drug- and fiber-type cannabis seeds. J Anal Toxicol
2000; 24: 715–7.
Nunn, JA, Rizza, F, Peters, ER.
The incidence of schizotypy among cannabis and alcohol users. J Nerv Ment Dis
2001; 189: 741–8.
Morgan, CJA, Muetzelfeldt, L, Curran, HV.
Attentional bias to incentive stimuli in heavy ketamine users. Psychol Med
2008; 4: 1–10.
Skopp, G, Strohbeck-Kuehner, P, Mann, K, Hermann, D.
Deposition of cannabinoids in hair after long-term use of cannabis. Forensic Sci Int
2007; 170: 46–50.
Mason, O, Linney, Y, Claridge, G.
Short scales for measuring schizotypy. Schizophr Res
2005; 78: 293–6.
Peters, ER, Joseph, SA, Garety, PA.
Measurement of delusional ideation in the normal population: introducing the PDI (Peters et al. Delusions Inventory). Schizophr Bull
1999; 25: 553–76.